Federated Hermes, Inc. Altimmune, Inc. Transaction History

Federated Hermes, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 31, 2024	SELL	$2.14 - $11.62 $4,309 - $23,402	-2,014 Reduced 94.33%	121 $1,000
Q3 2023 Nov 13, 2023	BUY	$2.4 - $3.45 $4,624 - $6,648	1,927 Added 926.44%	2,135 $5,000
Q2 2023 Aug 14, 2023	SELL	$3.45 - $5.97 $2,525 - $4,370	-732 Reduced 77.87%	208 $0
Q1 2023 May 08, 2023	BUY	$4.19 - $16.83 $3,938 - $15,820	940 New	940 $3,000
Q1 2020 May 13, 2020	SELL	$1.69 - $3.8 $625 - $1,406	-370 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$1.53 - $2.15 $341 - $479	223 Added 151.7%	370 $1,000
Q3 2019 Nov 14, 2019	BUY	$1.95 - $2.66 $286 - $391	147 New	147 $1,000

208

39.5M

1.94M

1.38M

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $300M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.